Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.33
-0.71 (-4.17%)
At close: Sep 8, 2025, 4:00 PM
16.29
-0.04 (-0.23%)
After-hours: Sep 8, 2025, 7:06 PM EDT
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts that cover Syndax Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $37.4, which forecasts a 129.03% increase in the stock price over the next year. The lowest target is $17 and the highest is $56.
Price Target: $37.4 (+129.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 8 | 8 | 8 | 9 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 11 | 11 | 11 | 12 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $20 → $24 | Strong Buy | Maintains | $20 → $24 | +46.97% | Sep 5, 2025 |
Guggenheim | Guggenheim | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +108.21% | Sep 4, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $46 → $51 | Strong Buy | Maintains | $46 → $51 | +212.31% | Aug 5, 2025 |
BTIG | BTIG | Strong Buy Maintains $43 → $56 | Strong Buy | Maintains | $43 → $56 | +242.93% | Aug 5, 2025 |
UBS | UBS | Strong Buy Maintains $37 → $35 | Strong Buy | Maintains | $37 → $35 | +114.33% | Jul 15, 2025 |
Financial Forecast
Revenue This Year
162.38M
from 23.68M
Increased by 585.73%
Revenue Next Year
315.29M
from 162.38M
Increased by 94.17%
EPS This Year
-3.28
from -3.72
EPS Next Year
-1.90
from -3.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 203.7M | 471.4M | |||
Avg | 162.4M | 315.3M | |||
Low | 120.8M | 164.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 760.3% | 190.3% | |||
Avg | 585.7% | 94.2% | |||
Low | 410.3% | 1.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.77 | -0.54 | |||
Avg | -3.28 | -1.90 | |||
Low | -3.67 | -2.95 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | |||
Avg | - | - | |||
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.